Mechanisms of Oncogenesis Research Program

肿瘤发生机制研究计划

基本信息

批准号：
10625757
负责人：
Lizi Wu
金额：
$ 7.78万
依托单位：
UNIVERSITY OF FLORIDA
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-06-01 至 2027-05-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10625757
关键词：
Abbreviations Address Affect Apoptotic Area Award BCL2L1 gene Basic Science Biology Biomedical Research Biometry Cancer Biology Cancer Burden Cancer Center Cancer Center Support Grant Cancer Control Catchment Area Chromatin Clinic Clinical Clinical Research Collaborations Colorectal Cancer Communities Community Outreach Confocal Microscopy Cytarabine DNA Tumor Viruses DNMT3a Development Direct Costs Disease Dose Educational Curriculum Enzymes Epigenetic Process Event Faculty Florida Flow Cytometry Focus Groups Fostering Funding Future Genetic Goals Grant Head Cancer Health Hematologic Neoplasms Human Human Herpesvirus 4 Human Herpesvirus 8 Immune response Immunity In Vitro Infrastructure Institution Joints Last Name Leadership Learning Legal patent Malignant Neoplasms Malignant neoplasm of lung Mentors Messenger RNA Methodology Methods MicroRNAs Mission Modeling Molecular Target Monitor Mus Mutation Neck Cancer Neoplastic Cell Transformation Oncogenes Pathway interactions Peer Review Peer Review Grants Phenotype Population Sciences Postdoctoral Fellow Predisposition Productivity Proteins Publications RNA Research Research Personnel Resource Sharing Role STK11 gene Science Signal Transduction Site Solid Source Strategic Planning Training Translating Translations Tumor Suppressor Genes Underrepresented Minority United States National Institutes of Health Universities Untranslated RNA Viral Woman Work base biomarker development citizen science clinical candidate clinical development clinical translation college community engagement equity, diversity, and inclusion graduate student human DNA in vivo Model innovation investigator-initiated trial malignant breast neoplasm meetings melanoma member microbiota multidisciplinary mutant next generation sequencing novel novel therapeutic intervention oncohistone precision medicine programs recruit success therapeutic RNA therapeutic development therapeutic target tobacco prevention treatment response treatment trial tumor tumor initiation tumor progression tumorigenesis virology working group

项目摘要

MECHANISMS OF ONCOGENESIS PROGRAM: ABSTRACT The objectives of the Mechanisms of Oncogenesis (MOO) program are to elucidate the deregulated genetic and epigenetic events that drive tumor initiation and progression and to identify cancer relevant therapeutic targets. MOO is led by Wu, an expert in cancer signaling and mouse tumor models, and Renne, an expert in tumor virology and non-coding RNAs. MOO is a multidisciplinary group of 38 members, representing 19 departments from 5 colleges. Since 2016, 20 faculty, including 14 early stage investigators (ESIs) were recruited since 2016. The scientific aims of MOO are to: 1) elucidate the role of genetic and epigenetic alterations in cancer; 2) define the role of regulatory RNAs in oncogenesis; and, 3) translate MOO discoveries into novel therapeutic approaches. In alignment with Aim 3, Guryanova discovered that DNMT3A mutant AML was highly sensitive to low dose cytarabine, which has led to the development of a treatment trial in collaboration with Al-Mansour (CTHR), fostered by the ADs for Basic Sciences and Clinical Research and the IIT Think Tank. MOO has a peer- reviewed funding base of >$9M/yr in direct costs (increased >10% since 2019), representing 59 peer-reviewed projects of which 24 are from NCI ($3.8M direct costs), including an NCI P01, NIH, and other peer-reviewed sources. Since 2019, 10 new grants have been awarded to newly recruited ESIs. MOO cultivates intra- and inter- programmatic interactions through working group focused meetings (Epigenetics, Tumor Virology, and Lung Cancer, a catchment area priority), seminars, and annual program retreats. These interactions led to 11 active multi-PI peer-reviewed grants and a multi-institutional NCI P01. The success of MOO collaborations is also demonstrated by 762 cancer-related publications since 2016, 20% with impact factors >10. Moreover, 19% of publications are inter-programmatic, 23% are intra-programmatic, and 74% are multi-institutional. MOO members were also granted 36 new patents. MOO mentors trained 162 graduate students and 71 postdocs, comprised of 45% women and 10% underrepresented minorities (URM). There were 14 trainees (9 women; 3 URM) supported by NIH training grants. Wu serves as the program liaison to community outreach and engagement (COE). She and Renne convey the impact of MOO research to community members and, in return, learn about their needs. Renne, working with COE, co-developed the UFHCC cancer curriculum for Citizen Scientists. MOO leadership and members are committed to increase diversity, equity, and inclusion through participation in recruitment of trainees and faculty, in coordination with and guidance from the AD for Diversity, Equity, and Inclusion. Future goals, in alignment with the strategic plan, Momentum 2027, will be focused on paradigm shifting basic discovery and identification of therapeutic targets with the goal of clinical translation with CTHR and CCPS members to address the cancer burden in the CA. MOO will enhance research in the areas of lung cancer and RNA biology. UFHCC will monitor success based on collaborative publications, new programmatic and MPI grants, and MOO discoveries translated into the clinic.

肿瘤生成计划的机制：摘要肿瘤发生机制（MOO）程序的目标是阐明失调的遗传和驱动肿瘤起步和进展并鉴定癌症相关的治疗靶标的表观遗传事件。 MOO由癌症信号传导和小鼠肿瘤模型的专家Wu和肿瘤专家Renne领导病毒学和非编码RNA。 Moo是一个由38名成员组成的多学科小组，代表19个部门来自5所大学。自2016年以来，自2016年以来就招募了20名教职员工，其中包括14名早期调查员（ESI）。 MOO的科学目的是：1）阐明遗传和表观遗传改变在癌症中的作用； 2）定义调节性RNA在肿瘤发生中的作用； 3）将MOO发现转化为新型治疗方法。在与AIM 3的一致性中，Guryanova发现DNMT3A突变体AML对低剂量Cytarabine，这导致与Al-Mansour合作开发了治疗试验（CTHR），由基础科学和临床研究的广告以及IIT智囊团培养。 Moo有一个同行审查的直接成本> 900万美元/年的资金基础（自2019年以来增长> 10％），代表59个同行评审其中24个来自NCI的项目（380万美元的直接费用），包括NCI P01，NIH和其他同行评审来源。自2019年以来，已向新招募的ESI授予了10笔新的赠款。 Moo培养内和间通过以工作组为中心的会议（表观遗传学，肿瘤病毒学和肺部）进行程序化相互作用癌症，集水区优先级），研讨会和年度课程撤退。这些相互作用导致11个活动多PI同行评审的赠款和多机构的NCI P01。 Moo合作的成功也是自2016年以来，由762个与癌症相关的出版物展示，影响因素> 10。此外，19％出版物是典型的，23％的题材是概括性的，有74％的人是多机构的。 Moo 成员还获得了36项新专利。 MOO导师培训了162名研究生和71个博士后，由45％的妇女和代表性不足的少数民族（URM）组成。有14名学员（9名妇女； 3名 URM）得到NIH培训补助金的支持。 Wu是社区外展的计划联络，订婚（COE）。她和Renne将MOO研究的影响传达给社区成员，作为回报了解他们的需求。与COE合作的Renne共同开发了公民的UFHCC癌症课程科学家。 MOO领导力和成员致力于通过参与受训者和教职员工的招聘，与广告多样性的协调和指导，公平和包容。未来的目标，与战略计划的一致，2027年动力，将重点关注范式转移基本发现和识别治疗靶标的目标，目的是以临床翻译为目标 CTHR和CCPS成员应对CA的癌症负担。 MOO将增强在肺癌和RNA生物学。 UFHCC将根据协作出版物，新的来监视成功程序化和MPI补助金，MOO发现转化为诊所。